Astellas Xospata comes up short again in bid to expand leukemia use

After gaining approval for Xospata to treat acute myeloid leukemia (AML) in 2018, Astellas has had difficulty expanding its label.

On Thursday, the company said (PDF) that a trial evaluating Xospata (gilteritinib) as a maintenance therapy following allogenic hematopoietic stem cell transplantation (HSCT) had failed. Patients in the study had FLT3 internal tandem duplication (ITD) mutated AML .